

CITATION REPORT

List of articles citing

Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future

DOI: 10.1111/liv.13643

Liver International, 2018, 38 Suppl 1, 47-51.

Source: <https://exaly.com/paper-pdf/69094248/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
248	A UPLC-MS/MS method for simultaneous quantification of pairs of oleanene- and ursane-type triterpenoid saponins and their major metabolites in mice plasma and its application to a comparative pharmacokinetic study.. 2018 , 8, 8586-8595		2
247	Food-drug interaction: Anabolic steroids aggravate hepatic lipotoxicity and nonalcoholic fatty liver disease induced by trans fatty acids. 2018 , 116, 360-368		17
246	Non-alcoholic fatty liver disease and the risk of urolithiasis: A systematic review and meta-analysis. 2018 , 97, e12092		11
245	Short- and long-term effects of high-fat diet feeding and voluntary exercise on hepatic lipid metabolism in mice. 2018 , 507, 291-296		4
244	Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. 2018 , 19,		25
243	Relationship between Experimental Diet in Rats and Nonalcoholic Hepatic Disease: Review of Literature. 2018 , 2018, 9023027		6
242	The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review. 2018 , 22, 2965-2974		23
241	Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearyl-CoA desaturase-1, lipase activity, leptin and resistin. 2018 , 16, 2938-2948		2
240	Prolonged inhibition of hepatocellular carcinoma cell proliferation by combinatorial expression of defined transcription factors. 2018 , 109, 3543-3553		24
239	Milk thistle (<i>Silybum marianum</i>): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. 2018 , 32, 2202-2213		157
238	Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?. 2018 , 30, 979-985		48
237	Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications. <i>Nutrients</i> , 2018 , 10,	6.7	25
236	Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases. <i>Nutrients</i> , 2018 , 10,	6.7	25
235	Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. <i>Nutrients</i> , 2018 , 10,	6.7	68
234	Curative effect of arjunolic acid from <i>Terminalia arjuna</i> in non-alcoholic fatty liver disease models. 2018 , 107, 979-988		13
233	The Effect of Nutrition Education Program on Overweight/Obese Patients with Non-Alcoholic Fatty Liver Disease: a Single-Blind Parallel Randomized Controlled Trial. 2019 , 8, 238-246		2
232	Hepatoprotective activity of raspberry ketone is mediated inhibition of the NF- κ B/TNF- α /caspase axis and mitochondrial apoptosis in chemically induced acute liver injury. 2019 , 8, 663-676		17

231	A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. 2019 , 13, 2917-2922	15
230	Pyroptosis in Liver Disease: New Insights into Disease Mechanisms. 2019 , 10, 1094-1108	48
229	The potential of antioxidant-rich Maoberry (<i>Antidesma bunius</i>) extract on fat metabolism in liver tissues of rats fed a high-fat diet. 2019 , 19, 294	8
228	A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis. 2019 , 20,	1
227	The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. 2019 , 20,	27
226	Mastiha (<i>Pistacia lentiscus</i>) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis. 2019 , 63, e1900927	12
225	Atherogenic index of plasma is a novel and strong predictor associated with fatty liver: a cross-sectional study in the Chinese Han population. 2019 , 18, 170	3
224	Effects of Hepatic Steatosis on Non-Invasive Liver Fibrosis Measurements Between Hepatitis B and Other Etiologies. 2019 , 9, 1961	4
223	A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease. 2019 , 13, 2260-2265	13
222	Nonalcoholic fatty liver disease in obese adolescents: the role of genetic polymorphisms. 2019 , 8, 179-180	1
221	Impact of different ectopic fat depots on cardiovascular and metabolic diseases. 2019 , 234, 21630-21641	70
220	Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. <i>Liver International</i> , 2019 , 39, 818-820	
219	Silybin Modulates Collagen Turnover in an In Vitro Model of NASH. 2019 , 24,	2
218	Telmisartan and/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: Implications of cross-talk between angiotensin, the sphingosine kinase/sphingosine-1-phosphate pathway, and TLR4 receptors. 2019 , 164, 252-262	19
217	THE CORRELATION OF NECK CIRCUMFERENCE AND INSULIN RESISTANCE IN NAFLD PATIENTS. 2019 , 56, 28-33	3
216	Ischaemia reperfusion injury in liver transplantation: Cellular and molecular mechanisms. <i>Liver International</i> , 2019 , 39, 788-801	7.9 95
215	Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. 2019 , 5, 1-10	30
214	Analysis of Flavonoids Bioactivity for Cholestatic Liver Disease: Systematic Literature Search and Experimental Approaches. 2019 , 9,	3

213	Comparison of FibroTouch and FibroScan for staging fibrosis in chronic liver disease: Single-center prospective study. 2019 , 51, 1323-1329		13
212	Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. 2019 , 10, 279		34
211	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. 2019 , 209, 22-38		18
210	Plant Sterol Ester of -Linolenic Acid Attenuates Nonalcoholic Fatty Liver Disease by Rescuing the Adaption to Endoplasmic Reticulum Stress and Enhancing Mitochondrial Biogenesis. <i>Oxidative Medicine and Cellular Longevity</i> , 2019 , 2019, 8294141	6.7	6
209	Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in C57bl/6 Models. <i>Nutrients</i> , 2019 , 11,	6.7	38
208	Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction. 2019 , 20,		18
207	Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. 2019 , 6, 1801585		66
206	Olive Oil, Palm Oil, and Hybrid Palm Oil Distinctly Modulate Liver Transcriptome and Induce NAFLD in Mice Fed a High-Fat Diet. 2018 , 20,		13
205	Use of a novel set of features based on texture anisotropy for identification of liver steatosis from ultrasound images: a simple method. 2019 , 78, 11105-11127		2
204	SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity. 2020 , 27, 329-344		38
203	The influence of dietary fatty acids on liver fat content and metabolism. 2020 , 79, 30-41		22
202	Adelmidrol protects against non-alcoholic steatohepatitis in mice. 2020 , 393, 777-784		2
201	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. 2020 , 46, 288-295		9
200	The Role of Bilirubin and the Other "Yellow Players" in Neurodegenerative Diseases. <i>Antioxidants</i> , 2020 , 9,	7.1	3
199	Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. 2020 , 18, 261		30
198	and reciprocally regulate expression and autophagy in nonalcoholic hepatic steatosis. 2021 , 17, 2415-2431		9
197	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. 2021 , 50, 101049		12
196	An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. 2020 , 14, 985-998		3

195	Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis. 2020 , 19, 472-481		6
194	Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes. 2020 , 11, 2057-2073		5
193	The common variant of rs6214 in insulin like growth factor 1 () gene: a potential protective factor for non-alcoholic fatty liver disease. 2020 , 1-6		5
192	Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. <i>Nutrients</i> , 2020 , 12,	6.7	13
191	Extracellular Vesicles in the Development of the Non-Alcoholic Fatty Liver Disease: An Update. 2020 , 10,		10
190	A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?. 2020 , 22, 2227-2240		8
189	Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare. 2020 , 2020, 7347068		0
188	Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. 2020 , 2020, 8822859		12
187	Current and Emerging Treatments for Non-alcoholic Steatohepatitis. 2020 , 19, 391-401		2
186	Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance. 2020 , 8, 1414		1
185	A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study. 2020 , 2020, 8852198		3
184	Diagnostic accuracy of B-Mode ultrasound and Hepatorenal Index for graduation of hepatic steatosis in patients with chronic liver disease. <i>PLoS ONE</i> , 2020 , 15, e0231044	3.7	9
183	Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. 2020 , 17, 34		10
182	Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west?. 2020 , 20, 139		8
181	Effects of garlic powder supplementation on insulin resistance, oxidative stress, and body composition in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. 2020 , 51, 102428		16
180	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. 2020 , 17, e1003149		18
179	Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation. <i>Nutrients</i> , 2020 , 12,	6.7	2
178	The water extract of <i>Sophorae tonkinensis Radix et Rhizoma</i> alleviates non-alcoholic fatty liver disease and its mechanism. 2020 , 77, 153270		3

177	Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults. 2020 , 17,	6
176	Association between periodontal disease, tooth loss and liver diseases risk. 2020 , 47, 1053-1063	15
175	The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. 2020 , 19, 148	2
174	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. 2020 , 36, 527-547	3
173	Non-alcoholic fatty liver disease (NAFLD) among underweight adults. 2020 , 38, 80-85	2
172	Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. 2020 , 22, e3160	1
171	Biomarker discovery for chronic liver diseases by multi-omics - a preclinical case study. 2020 , 10, 1314	14
170	Mean Arterial Pressure Is Related to Incident Nonalcoholic Fatty Liver Disease among the Nonobese Female with Normal Low-Density Lipoprotein Cholesterol Levels: A Large Cohort Study in China. 2020 , 2020, 3580840	
169	Oleuropein overrides liver damage in steatotic mice. 2020 , 65, 103756	7
168	Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial. 2020 , 21, 128	4
167	The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study. 2020 , 19, 18	5
166	Association of the rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2020 , 12,	6.7 4
165	Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. 2020 , 107, 154220	10
164	Effects of dapagliflozin and statins attenuate renal injury and liver steatosis in high-fat/high-fructose diet-induced insulin resistant rats. 2020 , 396, 114997	7
163	Coenzyme Q: Clinical Applications in Cardiovascular Diseases. <i>Antioxidants</i> , 2020 , 9,	7.1 27
162	Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial. 2020 , 124, 450-456	11
161	Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity. 2020 , 39, 75-83	2
160	Prolyl endopeptidase gene disruption attenuates high fat diet-induced nonalcoholic fatty liver disease in mice by improving hepatic steatosis and inflammation. 2020 , 8, 218	6

159	Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery. 2021 , 45, 374-382		0
158	Evolutionary conservation of long non-coding RNAs in non-alcoholic fatty liver disease. 2021 , 264, 118560		8
157	Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis. 2021 , 18, 131-142		21
156	Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2021 , 36, 1470-1478		17
155	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. 2021 , 15, 345-352		20
154	Exposure to nitenpyram during pregnancy causes colonic mucosal damage and non-alcoholic steatohepatitis in mouse offspring: The role of gut microbiota. 2021 , 271, 116306		8
153	Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. 2021 , 15, 25-40		3
152	A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. 2021 , 66, 4046-4057		0
151	Functional milk fat enriched in conjugated linoleic acid prevented liver lipid accumulation induced by a high-fat diet in male rats. 2021 , 12, 5051-5065		1
150	Hepatoprotective effect of seed extracts on paracetamol-induced rats. <i>Pharmaceutical Biology</i> , 2021 , 59, 31-39	3.8	2
149	Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China. 2021 , 18, 3082-3089		
148	Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease. 2021 , 10,		4
147	Association of liver enzymes with incident diabetes in US Hispanic/Latino adults. 2021 , 38, e14522		0
146	Application of artificial intelligence in chronic liver diseases: a systematic review and meta-analysis. 2021 , 21, 10		15
145	Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice. 2021 , 21, 418		8
144	NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. 2021 , 112, 1471-1480		2
143	Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study. 2021 , 1-9		
142	Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis. 2021 , 19,		13

141	A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. <i>Nutrients</i> , 2021 , 13,	6.7	3
140	Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. 2021 , 11,		4
139	Fortifying Butterfat with Soybean Oil Attenuates the Onset of Diet-Induced Non-Alcoholic Steatohepatitis and Glucose Intolerance. <i>Nutrients</i> , 2021 , 13,	6.7	1
138	LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. 2021 , 20, 28		9
137	Attenuation Imaging with Ultrasound as a Novel Evaluation Method for Liver Steatosis. 2021 , 10,		4
136	An insight into the role of telmisartan as PPAR- α dual activator in the management of nonalcoholic fatty liver disease. 2021 ,		3
135	Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?. 2021 , 320, G485-G495		5
134	Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. <i>PLoS ONE</i> , 2021 , 16, e0249491	3.7	2
133	Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin. 2021 , 19, 44		13
132	European NAFLD Preparedness Index Q Is Europe ready to meet the challenge of fatty liver disease?. 2021 , 3, 100234		13
131	Fuzhuan brick tea supplemented with areca nuts: Effects on serum and gut microbiota in mice. 2021 , 45, e13737		1
130	Statin use in patients with elevated serum hepatic transaminases at baseline: A meta-analysis. 2021 , 31, 1357-1364		1
129	Experimental liver models: From cell culture techniques to microfluidic organs-on-chip. <i>Liver International</i> , 2021 , 41, 1744-1761	7.9	4
128	Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis. 2021 , 21, 244		2
127	Waist-to-height ratio and non-alcoholic fatty liver disease in adults. 2021 , 21, 239		5
126	Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity. 2021 , 22,		1
125	Defining comprehensive models of care for NAFLD. 2021 , 18, 717-729		16
124	Effect of Mediterranean diet on liver enzymes: a systematic review and meta-analysis of randomised controlled trials. 2021 , 1-9		2

123	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. 2021 , 9, 892-902			3
122	A PRISMA-compliant meta-analysis of apolipoprotein C3 polymorphisms and nonalcoholic fatty liver disease. 2021 , 84, 923-929			0
121	Lipid lowering effects in hepatocytes of cassane-type diterpenoids from the seeds of <i>Caesalpinia minax</i> Hance. 2021 , 43, 163-168			
120	Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.. 2022 , 12, 362-371			
119	Broccoli Florets Supplementation Improves Insulin Sensitivity and Alters Gut Microbiome Population-A Steatosis Mice Model Induced by High-Fat Diet. 2021 , 8, 680241			4
118	Expression of Jejunal Taste Receptors in Women with Morbid Obesity. <i>Nutrients</i> , 2021 , 13,	6.7		0
117	Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: A randomized controlled trial. 2021 , 44, 130-135			6
116	A qualitative study of self-management experiences in people with non-alcoholic fatty liver disease. 2021 , 8, 3135-3142			1
115	Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography. 2021 , 76, 53-59			4
114	Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. 2021 , 12, e0115521			1
113	Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. <i>PLoS ONE</i> , 2021 , 16, e0255535	3.7		1
112	The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). 2021 , 13, e17320			0
111	The "GG" genotype of rs26802 variant in the ghrelin gene is a potential protective factor against nonalcoholic fatty liver disease. 2021 , 108, 342-352			0
110	Study on the Hepatoprotection of Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics. 2021 , 12, 727636			1
109	Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children. 2021 , e12852			2
108	Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. 2021 , 15, 461-465			0
107	The effect of pomegranate extract on anthropometric indices, serum lipids, glycemic indicators, and blood pressure in patients with nonalcoholic fatty liver disease: A randomized double-blind clinical trial. 2021 , 35, 5871-5882			1
106	Deep Learning Prediction of Voxel-Level Liver Stiffness in Patients with Nonalcoholic Fatty Liver Disease. 2021 , 3, e200274			1

105	Omega 3-rich <i>Camelina sativa</i> oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo-controlled clinical trial. 2021 , 75, e14744	2
104	Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. 2021 , 11, 17815	0
103	Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial. 2021 , 75, e14852	3
102	Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease. 2021 , 91, 153666	0
101	Hepatoprotective effect of trypsin/chymotrypsin against olanzapine-induced non-alcoholic steatohepatitis in rats. 2021 , 99, 1088-1096	
100	The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease. 2021 , 1-16	1
99	The Microbiome and Its Implications in Cancer Immunotherapy. 2021 , 26,	8
98	Visualization of quantitative lipid distribution in mouse liver through near-infrared hyperspectral imaging. 2021 , 12, 823-835	1
97	Predictive performance of eLIFT for liver inflammation and fibrosis in chronic liver diseases. 2021 , 18, 3599-3608	
96	Psychological Biomarker Profile in NAFLD/NASH with Advanced Fibrosis. 2020 , 205-223	3
95	Cannabinoids in Gastrointestinal Disorders. 2020 , 415-451	1
94	NADPH and Glutathione Redox Link TCA Cycle Activity to Endoplasmic Reticulum Homeostasis. 2020 , 23, 101116	16
93	Linking abdominal imaging traits to electronic health record phenotypes.	1
92	Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients. 2020 , 36, 387-390	2
91	A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy. 2018 , 11, 252-259	2
90	Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. <i>Nutrients</i> , 2020 , 12,	6.7 10
89	Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial. 2020 , 10, 373-382	5
88	Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. 2020 , 1, 51-74	8

87	Beneficial Effects of Low-Calorie-Carbohydrate/High-Agar Diet on Cardiometabolic Disorders Associated with Non-Alcoholic Fatty Liver Disease in Obese Rats. 2019 , 24, 400-409	3
86	Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. 2019 , 8, 923-928	12
85	Emerging roles of PHLPP phosphatases in metabolism. 2021 , 54, 451-457	0
84	Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China. 2021 , 20, 132	1
83	Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. 2021 , 20, 97	1
82	Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. 2021 ,	1
81	An Efficient Model of Non-alcoholic Fatty Liver Disease (NAFLD) Versus Current Experimental Models: Effects of Fructose, Fat, and Carbon Tetrachloride on NAFLD. 2021 , 21,	0
80	A Review of the Clinical Trials of Traditional Chinese Medicine in the Treatment of Nonalcoholic Fatty Liver Disease in Recent Ten Years. 2019 , 08, 247-253	
79	NADPH and glutathione redox link TCA cycle activity to endoplasmic reticulum stress.	
78	Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: A study protocol for a randomised, double-blind, placebo-controlled pilot trial.	
77	Advancing the global public health agenda for NAFLD: a consensus statement. 2021 ,	37
76	Overall clinical and economic impact of non-alcoholic fatty liver disease. 2021 , 113, 396-403	
75	Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver. 2020 , 48, 300060520978122	3
74	D-Pinitol Increases Insulin Secretion and Regulates Hepatic Lipid Metabolism in Msg-Obese Mice. 2020 , 92, e20201382	1
73	Predicting and elucidating the etiology of fatty liver disease using a machine learning-based approach: an IMI DIRECT study.	
72	Clinical efficacy of Silybum marianum seed extract in treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease: a narrative review. 2020 , 1, 12-26	
71	Lipidomic-based investigation into the therapeutic effects of polyene phosphatidylcholine and Babao Dan on rats with non-alcoholic fatty liver disease. 2021 , 36, e5271	
70	Albino mice with the point mutation at the tyrosinase locus show high cholesterol diet-induced NASH susceptibility. 2021 , 11, 21827	0

69	A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). 2021 , 1-7	2
68	 2020 , 47-52	
67	Effect of Cornus mas L. fruit extract on lipid accumulation product and cardiovascular indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial.. 2022 , 47, 51-57	1
66	GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. 2021 , 2021, 8936865	7
65	Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up. 2021 , 1	
64	Glycogenic Hepatopathy as the Etiology of Abnormal Liver Chemistries in an Uncontrolled Type I Diabetic Patient.. 2021 , 13, e19755	
63	Increasing risk factors of non-alcoholic fatty liver disease, a look into chronic periodontitis and insulin resistance.. 2022 ,	
62	Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico. 2022 , 7, 100151	0
61	MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.. 2021 , 8, 774079	2
60	Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease.. 2022 , 13, 830012	0
59	Perturbation of Wnt/ β Catenin Signaling and Sexual Dimorphism in Non-Alcoholic Fatty Liver Disease.. 2022 ,	
58	Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation.. <i>Antioxidants</i> , 2021 , 10,	7.1 2
57	Structural characterization and preventive effect on non-alcoholic fatty liver disease of oligosaccharides from .. 2022 ,	2
56	Hepatoprotective mechanism of on nonalcoholic fatty liver disease based on network pharmacology and experimental verification.. 2022 , 13, 5216-5235	1
55	Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. 2022 , 13, 836455	1
54	Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.. <i>PLoS ONE</i> , 2022 , 17, e0263931	3-7 2
53	Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn?. 2022 , 14, 304-318	1
52	Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD.. 2022 , 1	3

51	The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH).. 2022 , 23,		0
50	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. 2021 ,		7
49	Steroid-mediated liver steatosis is CD1d-dependent, while steroid-induced liver necrosis, inflammation, and metabolic changes are CD1d-independent.. 2022 , 22, 169		0
48	Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial.. <i>BMC Nutrition</i> , 2021 , 7, 86	2.5	0
47	Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK. <i>Pharmaceutical Biology</i> , 2022 , 60, 25-37	3.8	3
46	Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 842980	5.4	0
45	Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients.. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022 , 20, 68	3.1	
44	Styrylpyrones from <i>Phellinus linteus</i> Mycelia Alleviate Non-Alcoholic Fatty Liver by Modulating Lipid and Glucose Metabolic Homeostasis in High-Fat and High-Fructose Diet-Fed Mice. <i>Antioxidants</i> , 2022 , 11, 898	7.1	1
43	A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2022 , 2022, 1-15	6.7	0
42	Celastrol-Lac-BSA nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease.. <i>Journal of Controlled Release</i> , 2022 ,	11.7	4
41	Efficacy of aerobic and resistance exercises in improving visceral adipose in patients with non-alcoholic fatty liver: a meta-analysis of randomized controlled trials. <i>Zeitschrift Fur Gastroenterologie</i> ,	1.6	0
40	Inulin may prevent steatosis by suppressing Cannabinoid receptor-1 and Patatin-like phospholipase-3 expression in liver. <i>Nutrition</i> , 2022 , 111742	4.8	
39	The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. <i>Biomedicines</i> , 2022 , 10, 1487	4.8	0
38	Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial. <i>Nutrients</i> , 2022 , 14, 2509	6.7	1
37	The visceral fat area to hip circumference ratio (VHR) as a predictor for insulin resistance in a Chinese population with type 2 diabetes. <i>Obesity Facts</i> ,	5.1	0
36	The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia. <i>PLoS ONE</i> , 2022 , 17, e0271108	3.7	1
35	Total Flavonoids from <i>Chimonanthus nitens</i> Oliv. Leaves Ameliorate HFD-Induced NAFLD by Regulating the Gut-Liver Axis in Mice. <i>Foods</i> , 2022 , 11, 2169	4.9	0
34	A Meta-Analysis of Sleep Disorders and Nonalcoholic Fatty Liver Disease. Publish Ahead of Print,		

- 33 Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat. **2022**, 23, 9298
- 32 Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. **2022**, 17, 425-434 1
- 31 Long non-coding RNA in Non-alcoholic fatty liver disease. **2022**, 1-35 0
- 30 Automatic Detection of Steatosis in Ultrasound Images with Comparative Visual Labeling. **2022**, 408-418 0
- 29 African genetic ancestry and protection against fatty liver disease. **2022**, 42, 2122-2123 1
- 28 Effect of Spirulina (Formerly Arthrospira) Maxima against Ethanol-Induced Damage in Rat Liver. **2022**, 12, 8626 0
- 27 Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). **2022**, 2, 264-282 0
- 26 Chiliadenus iphionoides Reduces Body Weight and Improves Parameters Related to Hepatic Lipid and Glucose Metabolism in a High-Fat-Diet-Induced Mice Model of NAFLD. **2022**, 14, 4552 1
- 25 Ultrasound-based artificial intelligence in gastroenterology and hepatology. 28, 5530-5546 2
- 24 The role of iron metabolism in chronic diseases related to obesity. **2022**, 28, 0
- 23 Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization. **2022**, 0
- 22 Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. **2022**, 23, 14762 0
- 21 Correlation between Component Factors of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Nurses: An Observational and Cross-Sectional Study. **2022**, 19, 16294 0
- 20 Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers. 0
- 19 Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. **2022**, 23, 16226 1
- 18 Yinchen Linggui Zhugan decoction ameliorates high fat diet-induced nonalcoholic fatty liver disease by modulation of SIRT1/Nrf2 signaling pathway and gut microbiota. 13, 0
- 17 Hepatic lipidomics and proteomics analysis reveals the mechanism of Cyclocarya paliurus flavonoids in preventing non-alcoholic steatohepatitis in mice. **2022**, 99, 105341 0
- 16 CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation Dysfunction Associated with Nonalcoholic Fatty Liver Disease. **2023**, 16, 106 0

- 15 Show Me What You Have Inside—The Complex Interplay between SIBO and Multiple Medical Conditions—A Systematic Review. **2023**, 15, 90 1
- 14 A bibliometric analysis and visualization of nonalcoholic fatty liver disease from 2012 to 2021. 0
- 13 Physicians' Use of Digital Health Interventions in the Management of Nonalcoholic Fatty Liver Disease. **2023**, 27, 515-533 0
- 12 Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling. **2023**, 176, 113757 0
- 11 Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study. Volume 16, 345-363 1
- 10 Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). **2023**, 189, 106679 0
- 9 Fecal Metagenomics and Metabolomics Identifying Microbial Signatures in Non-Alcoholic Fatty Liver Disease. **2023**, 24, 4855 0
- 8 Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. **2023**, 0
- 7 Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Sub-Saharan Africa. **2023**, 26, 0
- 6 The combined effect of Raspberry Ketone with Resveratrol against oxidative stress and steatohepatitis in rats: Pharmacokinetic and pharmacodynamic studies. 0
- 5 Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo. 14, 0
- 4 Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study. **2023**, 11, 1110 0
- 3 Association of serum folate with prevalence of non-alcoholic fatty liver disease among adults (NHANES 2011-2018). 10, 0
- 2 Transient Elastography as the First-Line Assessment of Liver Fibrosis and Its Correlation with Serum Markers. **2023**, 59, 752 0
- 1 Effect of Cornus mas L. fruit extract on blood pressure, anthropometric and body composition indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial. **2023**, 56, 18-24 0